Advertisement

Hepatologie

  • M. Manns
  • K.-H. Meyer zum Büschenfelde
  • B. Möller
  • R. Dominik
  • H. Lobeck
  • U. Hopf
  • T. Poralla
  • T. H. Hütteroth
  • G. R. Pape
  • E. P. Rieber
  • J. Eisenburg
  • R. Hoffmann
  • G. Paumgartner
  • G. Riethmüller
  • K. Gmelin
  • G. Hasche
  • B. Flehmig
  • G. Sann
  • H. W. Doerr
  • B. Kommerell
  • H.-P. Schultheiss
  • P. Schwimmbeck
  • H.-D. Bolte
  • P. A. Berg
  • G. Ramadori
  • H. P. Dienes
  • D. Falke
  • L. Theilmann
  • Y. R. Stollman
  • J. L. Salisbury
  • R. J. Stockert
  • W. Stremmel
  • S. Kochwa
  • P. D. Berk
  • H. Hartmann
  • M. Nauck
  • F. Stöckmann
  • W. Creutzfeldt
  • G. Oehler
  • H. Bleyl
  • M. Büdinger
  • K. Matthes
  • K. Weigand
  • R. Raedsch
  • A. Stiehl
  • S. Walker
  • P. Czygan
  • M. Rössle
  • S. Jäckie
  • W. Gerok
  • L. Marosi
  • P. Ferenti
  • B. Dragosics
  • F. Kiss
  • C. Pollak
  • E. Minar
  • J. von Romatowski
  • R. Schuster
  • C. Niederau
  • A. Sonnenberg
  • J. Müller
  • W.-P. Fritsch
  • T. Brüster
  • G. Strohmeyer
  • H.-J. Bröker
  • G. E. Feurle
  • K.-H. Munderloh
  • H.-W. Altmann
  • G. Möckel
  • W. Hess
  • G. Gohrband
  • W. Kurtz
  • S. Gemeinhardt
  • M. Classen
  • S. Matera
  • B. Schumacher
  • H. Matern
  • W. Lehnert
  • R. Götz
  • H.-P. Buscher
  • M. Beger
  • J. Lohmann
  • P. Nauen
  • H. Schriewer
  • M. Clemens
  • U. Karbach
  • J. Veit
  • K. Ewe
  • J. Homann
  • S. Schneider
  • S. Rotter
  • B. Röttger
  • F. Kratz
  • F. Paul
  • W. Kamenisch
  • K. J. Matthes
  • H. K. Seitz
  • B. Simon
Conference paper
Part of the Verhandlungen der Deutschen Gesellschaft für innere Medizin book series (VDGINNERE, volume 89)

Zusammenfassung

Die chronisch aktive Hepatitis (CAH) ist ein ätiologisch heterogenes Krankheitsbild. Autoantikörper gegen ein mikrosomales Antigen aus Leber und Niere (LKM) scheinen eine Subgruppe der CAH zu charakterisieren (Rizetto et al. 1973, 1974) [1, 2]. In der bisher angewendeten Immunfluoreszenztechnik (IF) an Nierenschnitten können diese Antikörper nur sehr schwer von antimitochondrialen (AMA) und anderen zytoplasmatischen Antikörpern unterschieden werden. Es ist bisher nicht geklärt, ob bei der primär biliären Zirrhose (PBC) zusätzlich zu AMA LKM-Antikörper vorkommen. Mit der Immunfluoreszenz kann ein zusätzliches Auftreten von LKM-Antikörpern nicht differenziert werden. Außerdem stand bisher ein spezifisches serologisches Testsystem nicht zur Verfügung.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Rizetto M, Swana G, Doniach D (1973) Microsomal antibodies in active chronic hepatitis and other disorders. Clin Exp Immunol 15: 331–344Google Scholar
  2. 2.
    Rizetto M, Bianchi FB, Doniach D (1974) Characterization of the microsomal antigen related to a subclass of active chronic hepatitis. Immunology 26: 589–601Google Scholar
  3. 3.
    Manns M, Meyer zum Büschenfelde K-H (1982) A mitochondrial antigen — antibody system in cholestatic liver disease detected by radioimmunoassay. Hepatology 2: 1–7PubMedCrossRefGoogle Scholar
  4. 4.
    Smith MGM, Williams R, Walker G, Rizetto M, Doniach D (1974) Hepatic disorders associated with liver/kidney microsomal antibodies. Br Med J 2: 80–84PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Carolla G, Digeon M, Feldmann G, Jungers P, Drouet I, Bach JF (1977) Detection of hepatitis B antigen in circulating immune complexes in acute and chronic hepatitis. Scand J Immunol 6: 1267Google Scholar
  2. 2.
    Nydegger UE, Lambert PH, Gerber H, Miescher PA (1974) Circulating immune complexes in the serum of systemic lupus erythematodes and carriers of hepatitis B antigen. J Clin Invest 54: 297PubMedCrossRefGoogle Scholar
  3. 3.
    Wands IR, Mann E, Alpert E, Isselbacher KI (1975) The pathogenesis of arthritis associated with acute and hepatitis B surface antigen-positive hepatitis. J Clin Invest 55: 930PubMedCrossRefGoogle Scholar
  4. 4.
    Thomas HC, De Villiers D, Potter B, Hodgson H, Jain S, Jewell DP, Sherlock S (1978) Immune complexes in acute and chronic liver disease. Clin Exp Immunol 31: 150PubMedGoogle Scholar

Literatur

  1. Dienes H et al. (1982) Histologic observations in human hepatitis non-A, non-B. Hepatology 2: 562–571PubMedCrossRefGoogle Scholar
  2. Hütteroth TH et al. (1982) Cellular cytotoxicity against the human hepatoma cell line PLC/PRF/5 in patients with hepatitis B virus-induced chronic active hepatitis (CAH) and non-A, non-B (NANB) CAH. Liver 2: 285–291Google Scholar
  3. Meyer zum Büschenfelde K-H et al. (1979) Immunologic liver injury: the role of hepatitis B viral antigens and liver membrane antigens as targets. Prog Liver Dis 6: 407–424PubMedGoogle Scholar
  4. Vergani GM et al. (1979) Lymphocyte cytotoxicity to autologous hepatocytes in HBsAg-negative chronic active hepatitis. Clin Exp Immunol 38: 16–21PubMedGoogle Scholar

Literatur

  1. 1.
    Dienstag JL, Bhan AK (1980) Enhanced in vitro cell-mediated cytotoxicity in chronic hepatitis B virus infection: absence of specificity for virus-expressed antigen on target cell membranes. J Immunol 125: 2269–2276PubMedGoogle Scholar
  2. 2.
    Chisari FV, Bieber MS, Josepho GA, Xavier C, Anderson DS (1981) Functional properties of lymphocyte subpopulations in hepatitis B-virus infection. II. Cytotoxic effector cell killing of targets that naturally express hepatitis B surface antigen and liver specific lipoprotein. J Immunol 126: 45–49PubMedGoogle Scholar
  3. 3.
    Eddleston ALWF, Mondelli M, Mieli-Vergani G, Williams R (1982) Lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection. Hepatology (Suppl) 2: 122S–127SGoogle Scholar
  4. 4.
    James SP, Vierling JM, Strober W (1981) The role of the immune response in the pathogenesis of primary biliary cirrhosis. Semin Liver Dis 1: 322–337PubMedCrossRefGoogle Scholar
  5. 5.
    Rieber P, Lohmeyer J, Schendel DJ, Riethmüller G (1981) Human T-cell differentiation antigens characterizing a cytotoxic/suppressor T-cell subset. Hybridoma 11: 59–69CrossRefGoogle Scholar
  6. 6.
    Abo T, Balch CM (1981) A differentiation antigen of human NK and K cells identified by a monoclonal antibody (HNK1). J Immunol 127: 1024–1029PubMedGoogle Scholar
  7. 7.
    Koprowski H, Steplewski Z, Herlyn D, Herlyn M (1978) Studies of antibodies against human melanoma produced by somatic cell hybrids. Proc Natl Acad Sci USA 75: 3405–3409PubMedCrossRefGoogle Scholar
  8. 8.
    Reinherz EL, Kung PC, Pesando JM, Ritz J, Goldstein G, Schlossman SF (1979) Ia determinants on human T-cell subsets defined by monoclonal antibody. Activation stimuli required for expression. J Exp Med 150: 1472–1482PubMedCrossRefGoogle Scholar
  9. 9.
    Pape GR, Troye M, Perlmann P (1977) Characterization of cytolytic effector cells in peripheral blood of healthy individuals and cancer patients. J Immunol 118: 1919–1924PubMedGoogle Scholar
  10. 10.
    Pape GR, Rieber EP, Eisenburg J, Hoffmann R, Paumgartner G, Riethmüller G (1983) Involvement of the cytotoxic/suppressor T-cell subset in liver tissue injury of patients with acute and chronic liver dieseases. Gastroenterology (in press)Google Scholar
  11. 11.
    Dudley FJ, Giustino V, Sherlock S (1972) Cell-mediated immunity in patients positive for hepatitis associated antigen. Br Med J 4: 752–759Google Scholar
  12. 12.
    Gudat F, Bianchi L, Sonnabend W, Thiel G, Aenishaenstin W, Stalder GA (1975) Pattern of core and surface expression in liver tissue reflects state of specific immune response in hepatitis B. Lab Invest 32: 1–12PubMedGoogle Scholar
  13. 13.
    Popper H (1975) Clinical pathological correlation in viral hepatitis: The effect of the virus on the liver. Am J Pathol 81: 609–619PubMedGoogle Scholar
  14. 14.
    Edgington TS, Chisari FV (1975) Immunological aspects of hepatitis B virus infection. Am J Med Sci 270: 213–229CrossRefGoogle Scholar
  15. 15.
    Quinnan GV, Manischewitz JE, Ennis FA (1978) Cytotoxic T lymphocyte response to murine cytomegalovirus infection. Nature 273: 514–515CrossRefGoogle Scholar
  16. 16.
    Quinnan GV, Manischewitz JE (1979) The role of natural killer cells and antibody dependent cell-mediated cytotoxicity during murine cytomegalovirus infection. J Exp Med 150: 1549–1554PubMedCrossRefGoogle Scholar
  17. 17.
    Quinnan GV, Kirmani N, Esber E, Saral R, Manischewitz JE, Rogers JL, Rook AH, Santos GW, Burus WH (1981) HLA-restricted cytotoxic T-lymphocyte response to cytomegalovirus infection of bone marrow transplant recipients. J Immunol 126: 2036–2041PubMedGoogle Scholar
  18. 18.
    Quinnan GV, Kirmani N, Rook AH, Manischewitz JE, Jackson L, Moresci G, Santos GW, Saral R, Burus WH (1982) Cytotoxic T-cells in cytomegalovirus infection. HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med 307: 7–13PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Cohen BJ (1978) The IgM antibody response to the core antigen of hepatitis B virus. J Med Virol 3: 141–149PubMedCrossRefGoogle Scholar
  2. 2.
    Flehmig B, Ranke M, Berthold H, Gerth HJ (1979) A solid-phase radioimmunoassay for the detection of IgM antibodies to the hepatitis A virus. J Infect Dis 140: 169–175PubMedCrossRefGoogle Scholar
  3. 3.
    Gerlich WH, Luer W, Thommsen R (1980) Diagnosis of acute and inapparent hepatitis B virus infections by measurement of IgM antibody to hepatitis B core antigen. J Infect Dis 142: 95–101PubMedCrossRefGoogle Scholar
  4. 4.
    Hawkes RA, Boughton CR, Ferguson V, Lehman NI (1980) Use of immunoglobulin M antibody to hepatitis B core antigen in diagnosis of viral hepatitis. J Clin Microbiol 11: 581–583PubMedGoogle Scholar
  5. 5.
    Hoofnagle JH, Gerety R, Ni L, Barker L (1974) Antibody to hepatitis B core antigen. A sensitive marker of hepatitis B virus replication. N Engl J Med 290: 1336–1340PubMedCrossRefGoogle Scholar
  6. 6.
    Huschka U, Maier J, Rauterberg EW, Doerr HW (1982) Rapid separation of immunoglobulin M by affinity chromatography for detection of specific antibodies to rubellae and treponema pallidum. Eur J Clin Microbiol 1: 118–121PubMedCrossRefGoogle Scholar
  7. 7.
    Kryger P, Mathiesen LR, Aldershvile J, Nielsen JO (1981) Presence and meaning of anti-HBc-IgM as determined by ELISA in patients with acute type B hepatitis and healthy HBsAg carriers. Hepatology 1: 233–237PubMedCrossRefGoogle Scholar
  8. 8.
    Nakane PK, Kawavi A (1974) Peroxydase-labeled antibody. A new method of conjugation. J Histochem Cytochem 22: 1084–1091PubMedCrossRefGoogle Scholar
  9. 9.
    Roggendorf M, Deinhardt F,Frösner GG, Scheid R, Bayerl B, Zachoval R (1981) Immunoglobulin M antibodies to hepatitis B core antigen: Evaluation of enzyme immunoassay for diagnosis of hepatitis B virus infection. J Clin Microbiol 13: 618–626PubMedGoogle Scholar
  10. 10.
    Stahl S, MacKay P, Magazin M, Bruce SA, Murray K (1982) Hepatitis B virus core antigen: synthesis in E. coli and application in diagnosis. Proc Natl Acad Sci USA 79: 1606–1610PubMedCrossRefGoogle Scholar
  11. 11.
    Tedder RS, Wilson-Croome R (1980) Detection by radioimmunoassay of IgM class antibody to hepatitis B core antigen: a comparison of two methods. J Med Virol 6: 235–247PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Berg PA, Baum H (1980) Serology of primary biliary cirrhosis. Semin Immunopathol 3: 355–373CrossRefGoogle Scholar
  2. 2.
    Berg PA, Klein R, Lindborn-Fotinos J, Klöppel W (1982) The ATPase associated antigen (M2) — a marker antigen for the serological diagnosis of primary biliary cirrhosis. LancetGoogle Scholar
  3. 3.
    Miyachi K, Gupta RC, Dickson ER, Tan EM (1980) Precipitating antibodies to mitochondrial antigens with primary biliary cirrhosis. Clin Exp Immunol 39: 599–606PubMedGoogle Scholar
  4. 4.
    Lindenborn-Fotinos J, Sayers TJ, Berg PA (1982) Mitochondrial antibodies in primary biliary cirrhosis. VI. Association of the complement fixing antigen with a component of the mitochondrial F1ATPase complex. Clin Exp Immunol 50: 267–274PubMedGoogle Scholar
  5. 5.
    Schultheiß HP, Klingenberg M (1981) Immunochemical characterization of the adenine nucleotide translocator — an autoantigen in patients with anti-mitochondrial antibodies. Immunobiology 160: 107Google Scholar
  6. 6.
    Schultheiß HP, Klingenberg M (1981) Der ADP-, ATP-Carrier der Mitochondrien als organspezifisches Antigen bei Autoimmunerkrankungen. Verh Dtsch Ges Inn Med 87: 1145–1150Google Scholar
  7. 7.
    Schultheiß HP, Klingenberg M (1982) Organ- and conformation specificity of the adenine nucleotide translocator. Second European Bioenergetics Conference reports, pp 471–473Google Scholar
  8. 8.
    Schultheiß HP, Berg PA, Klingenberg M (1983) The mitochondrial adenine nucleotide translocator is an antigen in primary biliary cirrhosis (PBC). J Clin Exp Immunol (in press)Google Scholar
  9. 9.
    Schultheiß HP, Berg PA, Klingenberg M (1982) Der Adinin-Nucleotid-Translocator (ANT) als organspezifisches Antigen bei der primär biliären Zirrhose (PBC). Verh Dtsch Ges Inn Med 88: 1052–1057Google Scholar
  10. 10.
    Klingenberg M (1976) The ADP-ATP carrier in mitochondrial membranes. In: Martonosi A (ed) The enzymes of biological membranes, vol 3. Plenum Publ. Corp., New York, pp 383–438Google Scholar
  11. 11.
    Klingenberg M (1980) The ADP-ATP translocation in mitochondria, a membrane potential controlled transport. J Membrane Biol 56: 97–105CrossRefGoogle Scholar
  12. 12.
    Klöppel G, Kirchhof M, Berg PA (1982) Natural course of primary biliary cirrhosis. I. A morphological, clinical and serological analysis of 103 cases. Liver 2: 141 – 151PubMedGoogle Scholar
  13. 13.
    Berg PA, Hornberg JC, Bottazo GF, Doniach D (1981) Clinical significance of mitochondrial antibodies in relation to liver disease. LancetGoogle Scholar
  14. 14.
    Riccio H, Aquila H, Klingenberg M (1975) Solubilization of the carboxyatractylate binding protein from mitochondria. FEBS Lett 56: 129–132CrossRefGoogle Scholar
  15. 15.
    Riccio H, Aquila H, Klingenberg M (1975) Purification of the carboxyatractylate binding protein from mitochondria. FEBS Lett 56: 133–138PubMedCrossRefGoogle Scholar
  16. 16.
    Schultheiß HP, Klingenberg M (1983) Immunoelectrophoretic characterization of the ADP/ATP carrier from heart, kidney and liver. BBA (in press)Google Scholar
  17. 17.
    Rosenthal JD, Kozaburo H, Notkins AL (1972) Rapid micro-radioimmunoassay for measurement of antiviral antibody. J Immunol 109: 171–173PubMedGoogle Scholar
  18. 18.
    Zollinger WD, DalrympleJM, Artenstein MS (1976) Analysis of parameters affecting the solid phase radioimmunoassay quantitation of antibody to meningococcal antigens. J Immunol 117: 1788–1798PubMedGoogle Scholar
  19. 19.
    Kessler SW (1975) Rapid isolation of antigens from cells with a staphylococcal protein A-antibody adsorbent: Parameters of the interaction of the antibodyantigen complexes with protein A. J Immunol 115: 1617–1624PubMedGoogle Scholar
  20. 20.
    Palmieri F, Klingenberg M (1979) Direct methods for measuring metabolite transport and distribution in mitochondria. In: Fleischer S, Packer L (eds) Methods in enzymology, vol 56. Academic Press, London, pp 279–301Google Scholar

Literatur

  1. Arnheiter H et al. (1982) Adult mouse hepatocytes in primary monolayer culture express genetic resistance to mouse hepatitis virus type 3. J Immunol 129: 1275–1281PubMedGoogle Scholar
  2. Engler H et al. (1982) Experimental infection of imbred mice with herpes simplex virus lv. Comparison of interferon production and natural killer cell activity in susceptible and resistant adult mice. Arch Virol 74: 239–247PubMedCrossRefGoogle Scholar
  3. Wisse E et al. (1979) The investigation of sinusiodal cells: A new approach to the study of liver function. In: Popper H, Schaffner F (eds) Progress in liver diseases. Grune and Stratton, New York San Francisco London, p 153Google Scholar

Literatur

  1. 1.
    Ashwell G, Morell AG (1974) The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv Enzymol 41: 99–128PubMedGoogle Scholar
  2. 2.
    Cheung WY (1970) Cyclic 3′5′nucleotide phosphodiesterase. Demonstration of an activator. Biochem Biophys Res Commun 38: 533PubMedCrossRefGoogle Scholar
  3. 3.
    Kakiuchi S, Yamazaki R (1970) Calcium dependent phosphodiesterase activity and its activating factor (PAF) from brain. Biochem Biophys Res Commun 41: 1104–1110PubMedCrossRefGoogle Scholar
  4. 4.
    Pearse BMF (1975) Coated vesicles from pig brain: Purification and biochemical characterization. J Mol Biol 97: 93PubMedCrossRefGoogle Scholar
  5. 5.
    Pearse BMF (1976) Clathrin: A unique protein associated with intracellular transfer of membrane by coated vesicles. Proc Natl Acad Sci USA 73: 1255PubMedCrossRefGoogle Scholar
  6. 6.
    Salisbury JL, Condeelis JS, Satir P (1980) Role of coated vesicles, microfilaments, and calmodulin in receptor-mediated endocytosis by cultured B lymphoblastoid cells. J Cell Biol 87: 132–141PubMedCrossRefGoogle Scholar
  7. 7.
    Schwartz AL, Fridovich SE, Knowles BB, Lodish HF (1981) Characterization of the asialoglycoprotein receptor in a continuous hepatoma line. J Biol Chem 256: 8878–8881PubMedGoogle Scholar
  8. 8.
    Teo TS, Wang TH, Wang JH (1973) Purification and properties of the protein activator of bovine heart cyclic adenosine 3′5′ monophosphate. J Biol Chem 248: 588–595PubMedGoogle Scholar

Literatur

  1. 1.
    Reichen J, Berk PD (1979) Isolation of an organic anion binding protein from rat liver plasma membrane fractions by affinity chromatography. Biochem Biophys Res Commun 91: 484–489PubMedCrossRefGoogle Scholar
  2. 2.
    Tiribelli C, Lunazi G, Luciani GL, Panfili E, Gassin B, Liut G, Sandri G, Sottocasa G (1978) Isolation of a sulfobromophthalein-binding protein from hepatocyte plasma membrane. Biochim Biophys Acta 532: 105–112PubMedGoogle Scholar
  3. 3.
    Wolkoff AW, Chung CT (1980) Identification, purification and partial characterization of an organic anion binding protein from rat liver cell plasma membrane. J Clin Invest 65: 1152–1161PubMedCrossRefGoogle Scholar
  4. 4.
    Fisher MM, Boxam DL, Oda M, Phillips MJ, Yousef YM (1975) Characterization of rat liver cell plasma membranes. Proc Soc Exp Biol Med 150: 177–184PubMedGoogle Scholar
  5. 5.
    Reichen J, Blitzer BL, Berk PD (1981) Binding of unconjugated and conjugated sulfobromophthalein to rat liver plasma membrane fractions in vitro. Biochim Biophys Acta 640: 298–312PubMedCrossRefGoogle Scholar
  6. 6.
    Stremmel W, Potter BJ, Berk PD (1983) Studies of albumin binding to rat liver plasma membranes — implications for the albumin receptor hypothesis. Biochim Biophys Acta (in press)Google Scholar
  7. 7.
    Neville DM (1971) Molecular weight determination of protein-dodecyl sulfate complexes by gel electrophoresis in a discontinuous buffer system. J Biol Chem 246: 6328–6334PubMedGoogle Scholar
  8. 8.
    Gerber MA, Garfinkel E, Hirschman SZ, Thung SN, Panagiotatos T (1981) Immune and enzyme histochemical studies of a human hepatocellular carcinoma cell line producing hepatitis B surface antigen. J Immunol 126: 1085–1089PubMedGoogle Scholar
  9. 9.
    Berry NM, Friend DS (1969) High yield preparation of isolated rat liver parenchymal cells. J Cell Biol 43: 506–5020PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Caesar J, Shaldon S, Chiandussi L, Guevara L, Sherlock S (1961) The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function. Clin Sci 21: 43–57PubMedGoogle Scholar
  2. 2.
    Child CG III (1954) The hepatic circulation and portal hypertension. W. B. Saunders, PhiladelphiaGoogle Scholar
  3. 3.
    Creutzfeldt W, Frerichs H, Sickinger K (1970) Liver diseases and diabetes mellitus. In: Progress in liver disease, vol III. Grune & Stratton, New York London, pp 317–407Google Scholar
  4. 4.
    Creutzfeldt W, Hartmann H, Nauck M, Stöckmann F (1983) Liver disease and glucose homeostasis. In: Liver in metabolic diseases. MTP Press, Lancaster (in press)Google Scholar
  5. 5.
    DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237 : E214–E223Google Scholar
  6. 6.
    Greco AV, Bertoli A, Ghirlanda G, Manna R, Altomonte L, Rebuzzi AG (1980) Insulin resistance in liver cirrhosis: decreased insulin binding to circulating monocytes. Horm Metab Res 12: 577–581PubMedCrossRefGoogle Scholar
  7. 7.
    Harewood MS, Proietto J, Dudley F, Alford FP (1982) Insulin action and cirrhosis: insulin binding and lipogenesis in isolated adipocytes. Metabolism 31: 1241–1246PubMedCrossRefGoogle Scholar
  8. 8.
    Kurz G, Wallenfels K (1974) UV-Test mit Galactose-Dehydrogenase. In: Bergmeyer HU (Hrsg) Methoden der enzymatischen Analyse. Verlag Chemie, Weinheim, S 1324–1333Google Scholar
  9. 9.
    McGuire, EAH, Helderman JH, Tobin JD, Andres R, Berman M (1976) Effects of arterial versus venous sampling on analysis of glucose kinetics in manGoogle Scholar
  10. 10.
    Riggio O, Merli M, Cangiano C, Capocaccia R, Casino A, Lala A, Leonetti F, Mauceri M, Pepe M, Rossi Fanelli F, Savioli M, Tamburrano G, Capocaccia L (1982) Glucose intolerance in liver cirrhosis. Metabolism 31: 627–634PubMedCrossRefGoogle Scholar
  11. 11.
    Sherwin RS, Fisher M, Bessoff J, Snyder N, Hendler R, Conn HO, Felig P (1978) Hyperglucagonemia in cirrhosis: altered secretion and sensitivity to glucagon. Gastroenterology 74: 1224–1228PubMedGoogle Scholar
  12. 12.
    Taylor R, Heine R, Collins J, James O, Alberti KGMM (1982) Adipocyte insulin binding, adipocyte insulin sensitivity and insulin resistance in vivo in patients with hepatic cirrhosis. Diabetologia 23: 204CrossRefGoogle Scholar
  13. 13.
    Tygstrup N (1963) Determination of the hepatic galactose elimination capacity in man. Acta Physiol Scand 58: 162–172PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Keen H, Jarrett RJ, McCartney P (1982) The ten-Year follow up of the Bedord Survey (1962–1972): Glucose tolerance and diabetes. Diabetologia 22: 73–78PubMedCrossRefGoogle Scholar
  2. 2.
    Haslbeck M, Silberhorn H, Kraus B, Bachmann W (1980) Prognostic value of OGTT: ten Years follow up of patients with impaired and equivocal glucose tolerance. Diabetologia 19: 281Google Scholar
  3. 3.
    Creutzfeldt W, Frerichs H, Kraft W (1967) The intravenous tolbutamide test in liver disease. Acta Diabetol Lat (Suppl 1) 4: 205Google Scholar
  4. 4.
    Oehler G, Bleyl H, Matthes KJ (1982) Hyperinsulinemia in hepatic steatosis. Int J Obesity (Suppl 1) 6: 137–144Google Scholar
  5. 5.
    Oehler G, Bleyl H, Knecht M, Matthes KJ (1981) Hyperinsulinämie und gestörte Glukosetoleranz bei chronisch-entzündlichen Leberkrankheiten. Z Gastroenterol 19: 26–32PubMedGoogle Scholar
  6. 6.
    Oehler G, Bleyl H, Matthes KJ (1978) Glukosetoleranz und Insulinsekretion bei Patienten mit chronischen Leberkrankheiten. Med Welt 29: 1314PubMedGoogle Scholar
  7. 7.
    Neubauer M, Lindemann M, Rosak C, Schalk K, Kaltwasser P, Althoff PH (1982) Störungen von Kohlenhydratstoffwechsel und Endokrinium bei idopathischer Hämochromatose. Inn Med 9: 151–158Google Scholar
  8. 8.
    Johnston DG, Alberti KGMM, Wright R, Smith-Laing G, Stewart AM, Sherlock S, Faber O, Binder C (1978) C-peptide and insulin in liver disease. Diabetes (Suppl 1) 27:201PubMedGoogle Scholar
  9. 9.
    Klein B, Morgenstern S, Kaufmann JH (1966) A modified automated ferricyanide-phosphomolybdic acid procedure for serum or plasma glucose. Clin Chem 12: 816PubMedGoogle Scholar
  10. 10.
    Wide L, Axen R, Porath J (1967) Radioimmunosorbent assay for proteins. Chemical coplings of antibodies to insoluble dextrane. Immunochemistry 4: 381CrossRefGoogle Scholar
  11. 11.
    Heding LG (1975) Radioimmunological determination of human C-peptide in serum. Diabetologia 11: 541PubMedCrossRefGoogle Scholar
  12. 12.
    Keen H, Jarrett RJ, Alberti KGMM (1979) Diabetes mellitus: A new look at diagnostic criteria. Diabetologia 16: 283PubMedCrossRefGoogle Scholar
  13. 13.
    Oehler G (1981) Oraler Glukosetoleranztest bei Patienten mit chronischen Leberkrankheiten. Diagnostik 14: 234–238Google Scholar
  14. 14.
    Köbberling J, Kerlin A, Creutzfeldt W (1980) The reproducibility of the oral glucose tolerance test over long (5 Years) and short periods (1 week). Klin Wochenschr 58: 527PubMedCrossRefGoogle Scholar
  15. 15.
    Köbberling J, Creutzfeldt W (1970) Comparison of different methods for the evaluation of the oral glucose tolerance test. Diabetes 19:870PubMedGoogle Scholar
  16. 16.
    Otto H (1981) Diabetes mellitus: Labormethoden in Diagnostik und Verlaufskontrolle. Diagnostik 14: 3Google Scholar
  17. 17.
    Haslbeck M (1981) Diagnostische Probleme bei Diabetes mellitus. Internist 22: 187PubMedGoogle Scholar
  18. 18.
    Diabetes Data compiled 1977 (1978) US-Department of Health, Education and Welfare, DHEW Publication No (NIH) 78-1468, US-Government Printing Office, WashingtonGoogle Scholar
  19. 19.
    Ishii H, Mamori H, Takahashi H, Muraoka M, Arai M, Shigeta Y, Saito H, Tsuchiya M (1975) Klinische Untersuchungen zur Pathogenese des hepatogenen Diabetes. Leber Magen Darm 5: 52Google Scholar

Literatur

  1. 1.
    Rojkind M, Kershenobich D (1981) Hepatic fibrosis. Clin Gastroenterol 10: 737–754PubMedGoogle Scholar
  2. 2.
    Frei A et al. (1982) Serum procollagen-III-aminopeptide as index of liver fibrosis — new morphometric evidence. Hepatology 2: 733Google Scholar
  3. 3.
    Savolainen et al. (1983) Enzymes of collagen synthesis and type-III-procollagen aminopropeptide in the evaluation of D-penicillamine and medroxyprogesterone treatments of primary billiary cirrhosis. Gut 24: 136–142PubMedCrossRefGoogle Scholar
  4. 4.
    Raedsch R et al. (1982) Prokollagen-Typ-III-Peptid-Serum-konzentrationen bei Patienten mit chronisch persistierender und chronisch aktiver Hepatitis und Leberzirrhose und ihre diagnostische Wertigkeit. Z Gastroenterol 20: 703–709Google Scholar
  5. 5.
    Rohde H et al. (1979) Radioimmunoassay for type III procollagen peptide and its application to human liver disease. Eur J Clin Invest 9: 451–459PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Rohde H, Vargas L, Hahn E, Kalbfleisch H, Bruguera M, Timpl R (1979) Radioimmunoassay for type III-procollagen-peptide and its application to human liver disease. Eur J Clin Invest 9: 451–459PubMedCrossRefGoogle Scholar
  2. 2.
    Raedsch R, Stiehl A, Waldherr R, Mall G, Gmelin K, Götz R, Walker S, Czygan P, Kommerell B (1982) Procollagen-type III-peptide serum concentrations in chronic persistent and chronic active hepatitis and in cirrhosis of the liver and their diagnostic value. Z Gastroenterol 20: 738–743PubMedGoogle Scholar
  3. 3.
    Rubin E, Schaffner F, Popper H (1965) Primary biliary cirrhosis. Chronic non-suppurative destructive cholangitis. Am J Pathol 46: 387–407PubMedGoogle Scholar

Literatur

  1. 1.
    Denckla WD, Dewey HK (1967) The determination of tryptophan in plasma, liver and urine. J Lab Clin Med 69: 1188–1197Google Scholar
  2. 2.
    James H, Ziparo V, Jeppson B, Fischer JE (1979) Hyperammonaemia, plasma amino acid imbalance and bloodbrain amino acid transport: a unified theory of portalsystemic encephalopathy. Lancet 10: 772–775CrossRefGoogle Scholar
  3. 3.
    Rössle M, Herz R, Hiss W, Gerok W (1983) Der Tryptophan-Belastungstest als Funktionsparameter bei Lebererkrankungen. Klin Wochenschr 61: 277–283PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Beasly RP, Lin CC, Hwang LY, Chien CS (1981) Hepatocellular Carcinoma and hepatitis B virus. Lancet 11: 1129–1133CrossRefGoogle Scholar
  2. 2.
    Child CG, Turcotte JG (1964) Surgery and portal hypertension. In: Child CG (ed) The liver and portal hypertension. W.B. Saunders, Philadelphia, pp 50–56Google Scholar
  3. 3.
    Higgins J (1963) The geographic pathology of primary liver cancer. Cancer Res 23: 1624–1633Google Scholar
  4. 4.
    Lee FI (1967) Cirrhosis and hepatoma in alcoholics. Gut 7: 77–85CrossRefGoogle Scholar
  5. 5.
    Minar E, Pötzi R, Dragosics B, Hirschl M, Lochs H, Marosi L (1983) Notfallendoskopie bei Patienten mit Leberzirrhose. Leber Magen Darm 13: 21–26PubMedGoogle Scholar
  6. 6.
    Österreichische Staatsdruckerei (1979) Statistisches Handbuch für die Republik Österreich. Statistisches Zentralamt Wien, S 44–46Google Scholar
  7. 7.
    Ornata M, Ashcavi H, Choon-Tsek L, Peters RL (1978) Hepatocellular carcinoma in the USA. Etiologic considerations. Gastroenterology 76: 279–287Google Scholar
  8. 8.
    Shikata T (1976) Primary liver carcinoma and liver cirrhosis. In: Okuda K, Peters RL (eds) Hepatocellular carcinoma. J. Wiley & Sons Inc., New York, pp 63–71Google Scholar
  9. 9.
    Ugarte G, Donoso S (1978) Primary hepatic tumors in Chile. Remmer H, Bannsch P, Bolt HM, Popper H (eds) Primary liver tumors. MTP Press, Lancaster, pp 165–169Google Scholar
  10. 10.
    Wewalka F, Hadziyannis St, Pesendorfer FX, Dragosics B, Base W (1979) OMGE Study on prevalence of hepatitis B surface antigen in different liver diseases. Scand J Gastroenterol (Suppl 56) 14: 55–58Google Scholar

Literatur

  1. Allison DJ (1978) Therapeutic embolization. Br J Hosp Med 20: 707–715PubMedGoogle Scholar
  2. Allison DJ (1982) The nonsurgical management of metastatic endocrine tumors of the liver. In: Wilkins RA, Viamonte M (eds) Interventional radiology. Blackwell Scientific Publ., Oxford London Edinburgh Boston Melbourne, p 191Google Scholar
  3. Broder LE, Carter SK (1973) Pancreatic islet-cell carcinoma II: Results of therapy with streptozotocin in 52 patients. Ann Intern Med 79: 108–118PubMedGoogle Scholar
  4. Chuang VP, Wallace S (1981) Hepatic artery embolization in the treatment of hepatic neoplasms. Radiology 140: 51–58PubMedGoogle Scholar
  5. Chuang VP, Wallace S, Soo CS, Charnsangavej C, Bowers T (1982) Therapeutic ivalon embolization of hepatic tumors. Am J Roentgenol 138: 289–294Google Scholar
  6. Creutzfeldt W (1980) Endocrine tumors of the pancreas: Clinical, chemical and morphological findings. In: Fitzgerald PJ, Morrison AB (eds) The pancreas. Williams & Wilkins, Baltimore London, p 208Google Scholar
  7. Friesen SR (1982) Tumors of the endocrine pancreas. N Engl J Med 306: 580–590PubMedCrossRefGoogle Scholar
  8. Gelin LE, Lewis DH, Nilsson L (1968) Liver blood flow in man during abdominal surgery. II: The effect of hepatic artery occlusion on the blood flow through metastatic tumor nodules. Acta Hepatogastroenterol (Stuttg) 15: 21–24Google Scholar
  9. Moertel CG, Hanley JA, Johnson LA (1980) Streptozocin alone with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 303: 1189–1194PubMedCrossRefGoogle Scholar
  10. Spigos DG, Tan WS, Jonasson C (1981) Therapeutic embolization, techniques and clinical application. Surg Annu 13: 362–381Google Scholar
  11. Trede M, Raute M (1981) Möglichkeiten der chirurgischen Therapie von Lebermetastasen. Dtsch Med Wochenschr 106: 492–496PubMedCrossRefGoogle Scholar

Literatur

  1. Carr BD, Duncan JG (1976) Liver volume determination by ultrasound: a feasibility study. Br J Radiol 49: 776–778PubMedCrossRefGoogle Scholar
  2. Castell D, O’Brien KD, Muench H et al. (1969) Estimation of liver size in normal individuals. Ann Intern Med 70: 1183–1189PubMedGoogle Scholar
  3. DeLand FH, North WA (1968) Relationship between liver size and body size. Radiology 91: 1195–1198PubMedGoogle Scholar
  4. Fioroli W (1960) A method for the clinical determination of liver size. Triangle 4: 268–288Google Scholar
  5. Gladisch R (1981) Praxis der Ultraschalldiagnostik. Schattauer, Stuttgart New YorkGoogle Scholar
  6. Holder LE, Strife J, Padikal TN, Perkins PJ, Kerelanes JG (1975) Liver size determination in pediatrics using sonographic and scintigraphic techniques. Radiology 117: 349–353PubMedGoogle Scholar
  7. Kardel T, Holm HH, Rasmussen SN, Mortensen T (1971) Ultrasonic determination of liver and spleen volumes. Scand J Clin Lab Invest 27: 123–128PubMedCrossRefGoogle Scholar
  8. Koischwitz D (1979) Sonographische Lebervolumenbestimmung. Problematik, Methodik und praktische Bedeutung der Quantifizierung des Lebervolumens. Fortschr Röntgenstr 131: 243–248CrossRefGoogle Scholar
  9. Lutz H, Ehler R, Reichel L, Meyer P (1979) Stellenwert der Ultraschalldiagnostik bei Lebererkrankungen. Klinikarzt 8: 533–541Google Scholar
  10. Naftalis J, Leevy CM (1963) Clinical estimation of liver size. Am J Dig Dis 8: 236–243PubMedCrossRefGoogle Scholar
  11. Peternell WW, Schaefer JW, Schifi L (1966) Clinical evaluation of liver size and hepatic scintiscan. Am J Dig Dis 11: 346–350CrossRefGoogle Scholar
  12. Phaler GE (1926) The measurement of the liver by means of roentgen rays based upon a study of 502 cases. Am J Roentgenol Rad Ther Nucl Med 16: 558–564Google Scholar
  13. Rasmussen SN (1978) Liver volume determination by ultrasonic scanning. Dan Med Bull 25: 1–45PubMedGoogle Scholar
  14. Sapira JD, Williamson DL (1979) How big is the normal liver? Arch Intern Med 139: 971–973PubMedCrossRefGoogle Scholar
  15. Sullivan S, Krasner N, Williams R (1976) The clinical estimation of liver size: a comparison of techniques and an analysis of the source of error. Br Med JGoogle Scholar

Literatur

  1. 1.
    Bartoli E, Massarelli G, Solinas A, Faedda R, Chiandussi L (1979) Acute hepatitis with bridging necrosis due to hydralazine intake. Arch Intern Med 139: 698–699PubMedCrossRefGoogle Scholar
  2. 2.
    Enat R, Rader G, Barzilai D (1977) Leberschaden durch Adelphan. Schweiz Med Wochenschr 107: 657–658PubMedGoogle Scholar
  3. 3.
    Forster HS (1980) Hepatitis from hydralazine. Letter to the editor. N Engl J Med 302: 1362PubMedGoogle Scholar
  4. 4.
    Itoh S, Ichinoe A, Tsukada Y, Itoh Y (1981) Hydralazine induced hepatitis. Acta Hepatogastroenterol (Stuttg) 28: 13–16Google Scholar
  5. 5.
    Jori GP, Peschle C (1973) Hydralazine disease associated with transient granulomas in the liver. Gastroenterology 64: 1163–1167PubMedGoogle Scholar
  6. 6.
    Knoblauch M, Cueni B, Spycher M, Schmid M (1977) Dihydralazin-induzierte, akute Hepatitis bei IgM-Mangel. Schweiz Med Wochenschr 107: 651–656PubMedGoogle Scholar
  7. 7.
    Roschlau G, Baumgarten R, Winter H (1982) Hepatitis mit konfluierenden Nekrosen durch Depressan. Dtsch Gesundh Wesen 37: 709–712Google Scholar

Literatur

  1. 1.
    Allan RN, Thistle JL, Hofmann AF (1976) Lithocholate metabolism during chemotherapy for gallstone dissolution. Gut 17: 413–419PubMedCrossRefGoogle Scholar
  2. 2.
    Barnes S, Burhol PG, Zander R, Haggstrom G, Settine RL, Hirschowitz BI (1979) Enzymatic sulfation of glycochenodeoxycholic acid by tissue fractions from adult hamsters. J Lipid Res 20: 952–959PubMedGoogle Scholar
  3. 3.
    Bedi BS, Debas HT, Gillespie G, Gillespie IE (1971) Effect of bile salts on antral gastrin release. Gastroenterology 60: 256–262PubMedGoogle Scholar
  4. 4.
    Black RB, Naylor F, Stenhouse NS (1977) Gastric mucosal damage by taurine and glycine conjugates of chenodeoxycholic acid. Am J Dig Dis 22: 1106–1108PubMedCrossRefGoogle Scholar
  5. 5.
    Caspary WF (1975) Einfluß von Aspirin, Antacida, Alkohol und Gallensäuren auf die transmurale elektrische Potentialdifferenz des menschlichen Magens. Dtsch Med Wochenschr 100: 1263–1268PubMedCrossRefGoogle Scholar
  6. 6.
    Cheli R, Santi L, Ciancamerla G, Canciani G (1973) A clinical and statistical follow-up study of atrophic gastritis. Am J Dig Dis 18: 1061PubMedCrossRefGoogle Scholar
  7. 7.
    Classen M, v Hinüber G, Demling L (1968) Disaccharides of the gastric mucosa in chronic atrophic gastritis with intestinal metaplasia. Digestion 1: 52PubMedCrossRefGoogle Scholar
  8. 8.
    Cochran KM, Mackenzie JF, Russell RI (1975) Role of taurocholic acid in production of gastric mucosal damage after ingestion of aspirin. Br Med J 1: 183–185PubMedCrossRefGoogle Scholar
  9. 9.
    Correa P, Cuello C, Duque E (1970) Carcinoma and intestinal metaplasia of the stomach in Columbian migrants. J Natl Cancer Inst 44: 297PubMedGoogle Scholar
  10. 10.
    DeBarros SG, Balistieri WF, Soloway RD, Weiss SG, Miller PC, Soper K (1982) Response of total and individual serum bile acids to endogenous and exogenous bile acid input to the enterohepatic circulation. Gastroenterology 82: 647–652Google Scholar
  11. 11.
    Eastwood GL (1975) Effect of pH on bile salt injury to mouse gastric mucosa. Gastroenterology 68: 1456–1465PubMedGoogle Scholar
  12. 12.
    Editorial (1981) Bacteria in the stomach. Lancet 2: 906–907Google Scholar
  13. 13.
    Fisher MM, Magnusson R, Miyai K (1971) Bile acid metabolism in mammals. I. Bile acid-induced intrahepatic cholestasis. Lab Invest 21: 88–91Google Scholar
  14. 14.
    Gadacz TR, Allan RN, Mack E, Hofmann AF (1976) Impaired lithocholate sulfation in the rhesus monkey: A mechanism for chenodeoxycholate toxicity. Gastroenterology 70: 1125–1129PubMedGoogle Scholar
  15. 15.
    Himal HS, Boutros M, Weiser M (1974) The relationship between bile and hydrochloric acid in the pathogenesis of acute gastric erosions. Am J Gastroenterol 62: 405–409PubMedGoogle Scholar
  16. 16.
    Imai T, Kubo T, Watanabe H (1971) Chronic gastritis in Japanese with reference to high incidence of gastric carcinoma. J Natl Cancer Inst 47: 179PubMedGoogle Scholar
  17. 17.
    Ivey KJ, Clifton JA, Hubel KA, DenBesten L (1969) Effect of bile salts on back diffusion of hydrogen ions in the human gastric mucosa. J Lab Clin Med 74: 886Google Scholar
  18. 18.
    Kulkarni M, Barnes S (1981) Lithocholate metabolites are not involved in DNA damage in L1210 cells. Colonic Carcinogenesis Symposium, Titisee, 27.–28.5.81Google Scholar
  19. 19.
    Kurtz W, Leuschner U, Gemeinhardt S, Classen M (1982) Gallensäuren und ihre Sulphatester in der gesunden Schleimhaut von Magen und Duodenum. Z Gastroenterol 20: 489Google Scholar
  20. 20.
    Malhotra SL (1976) New approaches to the causation and prevention of cancers of epithelial surfaces. Med Hypotheses 2: 279–281PubMedCrossRefGoogle Scholar
  21. 21.
    Norton L, Mathews D, Avrum L, Eiseman B (1974) Pharmacological protection against swine stress ulcer. Gastroenterology 66: 503–508PubMedGoogle Scholar
  22. 22.
    O’Brien P, Silen W (1973) Effect of bile salts and aspirin on the gastric mucosal blood flow. Gastroenterology 64: 246–253PubMedGoogle Scholar
  23. 23.
    Ponz de Leon M, Carulli N, Loria P, Iori R, Zironi E (1980) Cholesterol absorption during bile acid feeding. Gastroenterology 78: 214–219PubMedGoogle Scholar
  24. 24.
    Reddy BS, Watanabe K (1979) Effect of cholesterol metabolites and promoting effect of lithocholic acid in colon carcinogenesis in germ-free and conventional F344 rats. Cancer Res 39: 1521–1524PubMedGoogle Scholar
  25. 25.
    Ritchie WP (1977) Bile acids, the “barrier”, and reflux-related clinical disorders of the gastric mucosa. Surgery 82: 192–200PubMedGoogle Scholar
  26. 26.
    Safaie-Shirazi S, DenBesten L, Hamza KN (1972) Absorption of bile salts from the gastric mucosa during hemorrhagic shock (36 581). Proc Soc Exp Med Biol 140: 924–927Google Scholar

Literatur

  1. Tserng KY, Klein PD (1977) Synthesis of 13C-labelled bile acids. J Lipid Res 18: 400–408PubMedGoogle Scholar
  2. Matern S, Sjövall J, Pomare EW, Heaton KW, Low-Beer TS (1975) Metabolism of deoxycholic acid in man. Med Biol 53: 107–113PubMedGoogle Scholar

Literatur

  1. DeWitt EH, Lack L (1980) Effects of sulfation patterns on intestinal transport of bile salt sulfate esters. Am J Physiol 238:G34–G39Google Scholar
  2. Low-Beer TS, Tyor MP, Lack L (1969) Effects of sulfation of taurolithocholic and glycolithocholic acids on their intestinal transport. Gastroenterology 56: 721–726Google Scholar

Literatur

  1. 1.
    Kramer W, Buscher H-P, Gerok W, Kurz G (1979) Bile salt binding to serum components. Eur J Biochem 102: 1–9PubMedCrossRefGoogle Scholar
  2. 2.
    Middelhoff G, Mordasini R, Stiehl A, Greten (1979) A bile-acid-rich high-density lipoprotein (HDL) in acute hepatitis. Scand J Gastroenterol 14: 267–272PubMedCrossRefGoogle Scholar
  3. 3.
    Record CO, Buxton B, Chase RA, Curzon G, Murray-Lyon IM, Williams R (1976) Plasma and brain amino acids in fulminant hepatic failure and their relationship to hepatic encephalopathy. Eur J Clin Invest 6: 387–394PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Balint JA, Beeler DA, Kyriakides EC, Treble DH (1971) The effect of bile salts upon lecithin synthesis. J Lab Clin Med 77: 122–133PubMedGoogle Scholar
  2. 2.
    Cahlin E, Jösson J, Nilsson S, Schersten T (1972) Synthesis of phospholipids and triglycerides in human liver slices. Scand J Clin Lab Invest 29: 109–114PubMedCrossRefGoogle Scholar
  3. 3.
    Isaksson B (1954) On the dissolving power of lecithin and bile salts for cholesterol in human bladder bile. Acta Soc Med Upsal 59: 296–306PubMedGoogle Scholar
  4. 4.
    Kennedy EP (1962) Biosynthesis of phosphatidylcholine. Harvey Lect 57: 143–171Google Scholar
  5. 5.
    Lohmann J, Nauen P, Lessing U, Schriewer H, Schönleben K, Clemens M (1980) Eigenschaften der CTP: Cholinphosphat-cytidyltransferase in der mikrosomalen Fraktion menschlicher Leberbiopsien. In: Zelder O, Fischer M, Eckert P, Bode JC (Hrsg) Experimentelle und klinische Hepatologie. Thieme, Stuttgart New York, S 285–290Google Scholar
  6. 6.
    Schölmerich J, Schmidt K, Kremer B, Becker M-S, Gerok W (1981) Differente Wirkung von Taurolithocholsäure und Chenodesoxycholsäure auf Membranstruktur und Funktion isolierter Hepatozyten. Klin Wochenschr 59: 655–668PubMedCrossRefGoogle Scholar
  7. 7.
    Vance DE, Choy PC (1979) How is phosphatidylcholine biosynthesis regulated. TIBS July: 145–149Google Scholar
  8. 8.
    Weinhold PA, Skinner RS, Sanders RD (1973) Activity and some properties of choline kinase, cholinephosphate cytidyltransferase and choline phosphotransferase during liver development in the rat. Biochim Biophys Acta 326: 43–51PubMedGoogle Scholar

Literatur

  1. 1.
    Best W, Becktel JM, Singleton JM, Kern K (1978) Development of a Crohn’s disease activity index. Gastroenterology 70: 439–444Google Scholar
  2. 2.
    Hepner GW, Laurence MD (1977) Dynamics of the glycine conjugates of cholic acid, chenodeoxycholic, deoxycholic and sulfolithocholic acid in man. Gastroenterology 72: 499–501PubMedGoogle Scholar
  3. 3.
    La Russo NF, Hofmann NE, Korman MG, Hofmann AF, Cowen AE (1978) Determinants of fasting and postprandial serum bile acid levels in healthy man. Dig Dis Sci 23: 385–391CrossRefGoogle Scholar
  4. 4.
    Suchy FS, Balistreri WF (1981) Ileal dysfunction in Crohn’s disease assessed by the postprandial bile acid response. Gut 22: 948–982PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Feely J et al. (1981) Reduction of liver blood flow and propranolol methabolism by cimetidine. N Engl J Med 304: 692–695PubMedCrossRefGoogle Scholar
  2. 2.
    Frenzel H et al. (1982) Protective effect of CO2-induced hyperventilation on hepatotoxicity elicited by carbon tetrachloride. Liver 2: 376–384PubMedGoogle Scholar
  3. 3.
    Kirch W et al. (1982) Der Einfluß von Cimetidin auf die Pharmakokinetik und Pharmakodynamik von Metoprolol. Propranolol und Atenolol. Verh Dtsch Ges Inn Med 88: 659–662Google Scholar
  4. 4.
    Klotz V, Reimann J (1980) Delaged clearance of diazepam due to cimetidine. N Engl J Med 302: 1012–1014PubMedCrossRefGoogle Scholar
  5. 5.
    Knodell RG (1980) Drug metabolism by rat and human hepatic microsomes in response to interaction with H2-receptor antagonists. Gastroenterology 82: 84–88Google Scholar
  6. 6.
    Moeschlin S (Hrsg) Tetrachlorkohlenstoff, Tetrachlormethan. In: Klinik und Therapie der Vergiftungen, 6. Aufl. Thieme, Stuttgart New York, S 297–303Google Scholar
  7. 7a.
    Puurunen J, Pelkonen O (1979a) Cimetidine inhibits microsomal drug metabolism in the rat. Eur J Pharmacol 55: 335–336PubMedCrossRefGoogle Scholar
  8. 7b.
    Puurunen J et al. (1979b) Cimetidine inhibits microsomal drug metabolism in man. Naunyn-Schmiedebergs Arch Pharmacol 308: R24Google Scholar
  9. 8.
    Recknagel RO (1967) Carbon tetrachloride hepatotoxicity. Pharmacol Rev 19: 145–208PubMedGoogle Scholar
  10. 9.
    Serlin MJ (1979) Cimetidine. Intoxication with oral anticoagulants in man. Lancet 2: 317–319PubMedCrossRefGoogle Scholar
  11. 10.
    Sieger CP et al. (1978) Antihepatotoxic activity of dithiocarb as compared with six other thio compounds in mice. Arch Toxicol (Berl) 41: 79–88CrossRefGoogle Scholar
  12. 11.
    Slater TF (1978) Biochemical studies on liver injury. In: Slater TF (ed) Biochemical mechanisms of liver injury. Academic Press, London, pp 1–44Google Scholar

Literatur

  1. 1.
    Puurunen J, Sotaniemi E, Pelkonen O (1980) Effect of cimetidine on microsomal drug metabolism in man. Eur J Clin Pharmacol 18: 185–187PubMedCrossRefGoogle Scholar
  2. 2.
    Serlin MJ, Mossman S, Sibeon RG, Breckenridge AM, Williams JRB, Atwood JL, Willoughby JMT (1979) Cimetidine: interaction with oral anticoagulants in man. Lancet 2: 317–319PubMedCrossRefGoogle Scholar
  3. 3.
    Klotz U, Reimann I (1980) Delayed clearance of diazepam due to cimetidine. N Engl J Med 302: 1012–1014PubMedCrossRefGoogle Scholar
  4. 4.
    Desmond PV, Patwardhan RV, Schenker S, Speeg KV Jr (1980) Cimetidine impairs elimination of chlordiazepoxide (Librium) in man. Ann Intern Med 93: 266–268PubMedGoogle Scholar
  5. 5.
    Neuvonen PJ, Tokola RA, Kaste M (1981) Cimetidine-phenytoin interaction: effect of serum phenytoin concentration and antipyrine test. Eur J Clin Pharmacol 21: 215–220PubMedCrossRefGoogle Scholar
  6. 6.
    Knodell RG, Holtzman JL, Crankshaw DL, Steele NM, Stanley LN (1982) Drug metabolism by rat and human hepatic microsomes in response to interaction with H2-receptor antagonists. Gastroenterology 82: 84–88PubMedGoogle Scholar
  7. 7.
    Desmond PV, Patwardhan R, Parker R, Schenker S, Speeg KV Jr (1980) Effect of cimetidine and other antihistaminics on the elimination of aminopyrine, phenacetin and caffeine. Life Sci 26: 1261–1268PubMedCrossRefGoogle Scholar
  8. 8.
    Pelkonen O, Puurunen J (1980) The effect of cimetidine on in vitro and in vivo microsomal drug metabolism in the rat. Biochem Pharmacol 29: 3075–3080PubMedCrossRefGoogle Scholar
  9. 9.
    Speeg KV Jr, Patwardhan RV, Avant GR, Mitchell MC, Schenker S (1982) Inhibition of microsomal drug metabolism by histamine H2-receptor antagonists studied in vivo and in vitro in rodents. Gastroenterology 82: 89–96PubMedGoogle Scholar
  10. 10.
    Drew R, Rowell J, Grygiel J (1981) Cimetidine: a specific inhibitor of hepatic aryl hycrocarbon hydroxylase (AHH) in the rat. Res Commun Chem Pathol Pharmacol 33: 81–93PubMedGoogle Scholar
  11. 11.
    Henry DA, MacDonald IA, Kitchingman G, Bell GD, Langman MJS (1980) Cimetidine and ranitidine: comparison of effects on hepatic drug metabolism. Br Med J 281: 775–777PubMedCrossRefGoogle Scholar
  12. 12.
    Lieber CS, DeCarli LM (1970) Hepatic microsomal ethanol oxidizing system (MEOS): in vitro characteristics and adaptive properties in vivo. J Biol Chem 245: 2505–2512PubMedGoogle Scholar
  13. 13.
    Salaspuro MP, Lieber CS (1978) Non uniformity of blood ethanol elimination: its exaggeration after chronic consumption. Ann Clin Res 10: 294–297PubMedGoogle Scholar
  14. 14.
    Lieber CS, DeCarli LM (1970) Quantitative relationship between the amount of dietary fat and the severity of the alcoholic fatty liver. Am J Clin Nutr 23: 474–478PubMedGoogle Scholar
  15. 15.
    Puurunen J, Pelkonen O (1979) Cimetidine inhibits microsomal drug metabolism in the rat. Eur J Pharmacol 55: 335–336PubMedCrossRefGoogle Scholar
  16. 16.
    Lieber CS (1977) Metabolism of ethanol. In: Lieber CS (ed) Metabolic aspects of alcoholism. MTP Press, Lancaster, pp 1–30CrossRefGoogle Scholar

Copyright information

© J. F. Bergmann Verlag, München 1983

Authors and Affiliations

  • M. Manns
    • 1
  • K.-H. Meyer zum Büschenfelde
    • 1
  • B. Möller
    • 2
  • R. Dominik
    • 2
  • H. Lobeck
    • 3
  • U. Hopf
    • 4
  • T. Poralla
    • 5
  • T. H. Hütteroth
    • 5
  • G. R. Pape
    • 6
  • E. P. Rieber
    • 7
  • J. Eisenburg
    • 8
  • R. Hoffmann
    • 9
  • G. Paumgartner
    • 10
  • G. Riethmüller
    • 11
  • K. Gmelin
    • 12
  • G. Hasche
    • 12
  • B. Flehmig
    • 13
  • G. Sann
    • 13
  • H. W. Doerr
    • 13
  • B. Kommerell
    • 12
    • 25
    • 49
  • H.-P. Schultheiss
    • 14
  • P. Schwimmbeck
    • 14
  • H.-D. Bolte
    • 14
  • P. A. Berg
    • 15
  • G. Ramadori
    • 16
  • H. P. Dienes
    • 16
  • D. Falke
    • 17
  • L. Theilmann
    • 18
  • Y. R. Stollman
    • 18
  • J. L. Salisbury
    • 18
  • R. J. Stockert
    • 18
  • W. Stremmel
    • 19
  • S. Kochwa
    • 20
  • P. D. Berk
    • 20
  • H. Hartmann
    • 21
  • M. Nauck
    • 21
  • F. Stöckmann
    • 21
    • 29
  • W. Creutzfeldt
    • 21
    • 31
  • G. Oehler
    • 22
  • H. Bleyl
    • 23
  • M. Büdinger
    • 22
  • K. Matthes
    • 22
  • K. Weigand
    • 24
  • R. Raedsch
    • 25
  • A. Stiehl
    • 25
  • S. Walker
    • 25
  • P. Czygan
    • 25
  • M. Rössle
    • 26
  • S. Jäckie
    • 26
  • W. Gerok
    • 26
  • L. Marosi
    • 27
  • P. Ferenti
    • 28
  • B. Dragosics
    • 28
  • F. Kiss
    • 28
  • C. Pollak
    • 27
  • E. Minar
    • 27
  • J. von Romatowski
    • 30
  • R. Schuster
    • 30
  • C. Niederau
    • 32
  • A. Sonnenberg
    • 32
  • J. Müller
    • 32
  • W.-P. Fritsch
    • 32
  • T. Brüster
    • 33
  • G. Strohmeyer
    • 32
  • H.-J. Bröker
    • 34
  • G. E. Feurle
    • 34
  • K.-H. Munderloh
    • 34
  • H.-W. Altmann
    • 35
  • G. Möckel
    • 36
  • W. Hess
    • 36
  • G. Gohrband
    • 36
  • W. Kurtz
    • 37
  • S. Gemeinhardt
    • 37
  • M. Classen
    • 37
  • S. Matera
    • 26
  • B. Schumacher
    • 26
  • H. Matern
    • 26
  • W. Lehnert
    • 26
  • R. Götz
    • 25
  • H.-P. Buscher
    • 42
  • M. Beger
    • 42
  • J. Lohmann
    • 38
  • P. Nauen
    • 38
  • H. Schriewer
    • 38
  • M. Clemens
    • 39
  • U. Karbach
    • 40
  • J. Veit
    • 41
  • K. Ewe
    • 41
  • J. Homann
    • 42
  • S. Schneider
    • 43
  • S. Rotter
    • 44
  • B. Röttger
    • 45
  • F. Kratz
    • 46
  • F. Paul
    • 47
  • W. Kamenisch
    • 48
  • K. J. Matthes
    • 48
  • H. K. Seitz
    • 49
  • B. Simon
    • 49
  1. 1.I. Med. Klinik und Poliklinik MainzDeutschland
  2. 2.Innere Medizin und PoliklinikDeutschland
  3. 3.Patholog. Inst.Deutschland
  4. 4.Innere Medizin und Poliklinik, Klinikum CharlottenburgFU BerlinDeutschland
  5. 5.I. Med. Klinik und Poliklinik MainzDeutschland
  6. 6.Med. Klinik II, Klinikum Großhadern und Inst. für ImmunologieUniv. MünchenDeutschland
  7. 7.Inst. für ImmunologieUniv. MünchenDeutschland
  8. 8.Med. Klinik II, Klinikum GroßhadernUniv. MünchenDeutschland
  9. 9.Inst. für ImmunologieUniv. MünchenDeutschland
  10. 10.Med. Klinik II, Klinikum GroßhadernUniv. MünchenDeutschland
  11. 11.Inst. für ImmunologieUniv. MünchenDeutschland
  12. 12.Abt. 1.1.4Med. Univ.-Klinik HeidelbergDeutschland
  13. 13.Inst. für VirologieUniv. HeidelbergDeutschland
  14. 14.Med. Klinik I, Klinikum GroßhadernUniv. MünchenDeutschland
  15. 15.Med. KlinikUniv. TübingenDeutschland
  16. 16.Patholog. Inst.Deutschland
  17. 17.Virolog. Abt. des Mikrobiolog. Inst.Univ. MainzDeutschland
  18. 18.Albert-Einstein-College of MedicineBronxUSA
  19. 19.Med. Klinik D der Med. EinrichtungenUniv. DüsseldorfDeutschland
  20. 20.Dept. of Med.Mount Sinai School of MedicineNew YorkUSA
  21. 21.Med. Univ.-Klinik GöttingenDeutschland
  22. 22.Zentrum für Innere Medizin GießenDeutschland
  23. 23.Inst. für Klin. Chemie GießenDeutschland
  24. 24.Inst. für Klin. Pharmakologie BernDeutschland
  25. 25.Med. Univ.-KlinikHeidelbergDeutschland
  26. 26.Med. Univ.-KlinikFreiburgDeutschland
  27. 27.I. Med. Univ.-Klinik WienÜsterreich
  28. 28.I. Univ.-Klinik für Gastroenterologie und Hepatologie WienÜsterreich
  29. 29.Abt. Gastroenterologie und StoffwechselDeutschland
  30. 30.Abt. RöntgendiagnostikDeutschland
  31. 31.Abt. Gastroenterologie und StoffwechselMed. Univ.-Klinik GöttingenDeutschland
  32. 32.Med. Klinik D und PoliklinikUniv. DüsseldorfDeutschland
  33. 33.Inst. für Blutgerinnungs- und TransfusionswesenUniv. DüsseldorfDeutschland
  34. 34.Med. Univ.-Poliklinik HeidelbergDeutschland
  35. 35.Patholog. Inst.Univ. WürzburgDeutschland
  36. 36.Krankenhaus TABEAHamburgDeutschland
  37. 37.Abt. Gastroenterologie, Zentrum für Innere MedizinUniv.-Klinikum FrankfurtDeutschland
  38. 38.Med. Univ.-Klinik und Poliklinik MünsterDeutschland
  39. 39.Chirurg. Univ.-Klinik und Poliklinik MünsterDeutschland
  40. 40.Inst. für Pharmakologie und ToxikologieUniv. des Saarlandes HomburgDeutschland
  41. 41.I. Med. Klinik und PoliklinikUniv.-Klinik MainzDeutschland
  42. 42.Zentrum für Innere Medizin am KlinikumUniv. GießenDeutschland
  43. 43.Zentrum für Klin. Chemie, Klin. Immunologie und Humangenetik am Inst. für Klin. Chemie und PathobiochemieUniv. GießenDeutschland
  44. 44.Zentrum für Innere Medizin am KlinikumUniv. GießenDeutschland
  45. 45.Zentrum für Pathologie am KlinikumUniv. GießenDeutschland
  46. 46.Zentrum für Innere Medizin am KlinikumUniv. GießenDeutschland
  47. 47.II. Med. Klinik am Klinikum IngolstadtDeutschland
  48. 48.Zentrum für Innere Medizin am KlinikumUniv. GießenDeutschland
  49. 49.Abt. für GastroenterologieMed. Univ.-Klinik HeidelbergDeutschland

Personalised recommendations